J. Lipford

发表

Nucleosomes positioned by ORC facilitate the initiation of DNA replication.

S. Bell, J. Lipford, S P Bell, 2001, Molecular cell.

Diverse roles for ubiquitin-dependent proteolysis in transcriptional activation

R. Deshaies, J. Lipford, J. Lipford, 2003, Nature Cell Biology.

Mutation in the DNA mismatch repair gene homologue hMLH 1 is associated with hereditary non-polyposis colon cancer

D. Ward, A. Lindblom, R. Kolodner, 1994, Nature.

Mutational analysis of the hMSH2 gene reveals a three base pair deletion in a family predisposed to colorectal cancer development.

R. Scott, J. Torhorst, T. Bishop, 1994, Human molecular genetics.

Somatic mutations in the hMSH2 gene in microsatellite unstable colorectal carcinomas.

R. Lothe, R. Kolodner, A. Børresen, 1995, Human Molecular Genetics.

Discovery of imidazopyridazines as potent Pim-1/2 kinase inhibitors.

Kristin L. Andrews, B. Herberich, Matthew R. Lee, 2016, Bioorganic & medicinal chemistry letters.

The discovery and optimization of aminooxadiazoles as potent Pim kinase inhibitors.

Kristin L. Andrews, B. Herberich, Matthew R. Lee, 2015, Bioorganic & medicinal chemistry letters.

A putative stimulatory role for activator turnover in gene expression

R. Deshaies, Y. Chi, J. Lipford, 2005, Nature.

Structure of the human MSH2 locus and analysis of two Muir-Torre kindreds for msh2 mutations.

D. Bishop, R. Kolodner, J. Burn, 1994, Genomics.

Mercapturate pathway metabolites of sotorasib, a covalent inhibitor of KRASG12C, are associated with renal toxicity in the Sprague Dawley rat.

W. Humphreys, J. Lipford, J. Werner, 2021, Toxicology and applied pharmacology.

A Systematic Interrogation of MHC Class I Peptide Presentation Identifies Constitutive and Compensatory Protein Degradation Pathways

David J. Sherman, Jennifer L Mamrosh, Michael J. Sweredoski, 2021, bioRxiv.

Discovery of 1H-pyrazol-3(2H)-ones as potent and selective inhibitors of protein kinase R-like endoplasmic reticulum kinase (PERK).

Kristin L. Andrews, D. Powers, R. Kendall, 2015, Journal of medicinal chemistry.

Adaptive exchange sustains cullin–RING ubiquitin ligase networks and proper licensing of DNA replication

J. Weissman, R. Deshaies, S. Garbis, 2022, Proceedings of the National Academy of Sciences of the United States of America.

LKB1 loss rewires JNK-induced apoptotic protein dynamics through NUAKs and sensitizes KRAS-mutant NSCLC to combined KRASG12C + MCL-1 blockade

R. Heist, W. Haas, R. Morris, 2022, bioRxiv.

Profiling of diverse tumor types establishes the broad utility of VHL-based ProTaCs and triages candidate ubiquitin ligases

O. Homann, J. Lipford, D. Mohl, 2022, iScience.

Discovery of a covalent inhibitor of KRASG12C (AMG 510) for the treatment of solid tumors.

N. Chen, J. McCarter, K. Rex, 2019, Journal of medicinal chemistry.

Discovery of N-(1-Acryloylazetidin-3-yl)-2-(1H-indol-1-yl)acetamides as Covalent Inhibitors of KRASG12C.

Iain D G Campuzano, R. Fucini, Andrew M. Sawayama, 2019, ACS medicinal chemistry letters.

Differential inhibition of HIV-1 preintegration complexes and purified integrase protein by small molecules.

F. Bushman, C. Farnet, J. Lipford, 1996, Proceedings of the National Academy of Sciences of the United States of America.

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

J. Desai, R. Govindan, W. Ouyang, 2019, Nature.

A nanoparticle vaccine that targets neoantigen peptides to lymphoid tissues elicits robust antitumor T cell responses

H. Phee, Charles Glaus, J. Lipford, 2020, npj Vaccines.

A nanoparticle vaccine that targets neoantigen peptides to lymphoid tissues elicits robust antitumor T cell responses

J. Johnston, H. Phee, Charles Glaus, 2020, NPJ vaccines.

Diverse alterations associated with resistance to KRAS(G12C) inhibition

M. Berger, J. Reis-Filho, B. Weigelt, 2021, Nature.

Mutation in the Mismatch Repair Gene Msh6 Causes Cancer Susceptibility

R. Kucherlapati, T. Kunkel, J. Pollard, 1997, Cell.

Microsatellite instability, mismatch repair deficiency, and genetic defects in human cancer cell lines.

T. Kunkel, J. Barrett, R. Kolodner, 1995, Cancer research.

Human Immunodeficiency Virus Type 1 cDNA Integration: New Aromatic Hydroxylated Inhibitors and Studies of the Inhibition Mechanism

F. Bushman, C. Farnet, J. Lipford, 1998, Antimicrobial Agents and Chemotherapy.

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.

J. Desai, R. Govindan, J. Krauss, 2020, The New England journal of medicine.

Gal4 turnover and transcription activation

R. Deshaies, J. Lipford, W. Tansey, 2009, Nature.

Mutation screening in the hMLH1 gene in Swedish hereditary nonpolyposis colon cancer families.

A. Lindblom, R. Kolodner, M. Nordenskjöld, 1995, Cancer research.

Unfolded Protein Response in Cancer: IRE1α Inhibition by Selective Kinase Ligands Does Not Impair Tumor Cell Viability.

A. Tasker, R. Kendall, J. Lipford, 2015, ACS medicinal chemistry letters.

Nonclinical Safety Profile of Sotorasib, a KRASG12C-Specific Covalent Inhibitor for the Treatment of KRAS p.G12C-Mutated Cancer

J. Lipford, J. Werner, T. Monticello, 2021, International journal of toxicology.

A "Click Chemistry Platform" for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation.

J. McCarter, J. Lipford, D. Mohl, 2017, Journal of medicinal chemistry.

Structure of the human MLH1 locus and analysis of a large hereditary nonpolyposis colorectal carcinoma kindred for mlh1 mutations.

R. Kolodner, J. Burn, M. Kane, 1995, Cancer research.

Discovery of ( R)-8-(6-Methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4- b]pyrrol-2-yl)-3-(1-methylcyclopropyl)-2-((1-methylcyclopropyl)amino)quinazolin-4(3 H)-one, a Potent and Selective Pim-1/2 Kinase Inhibitor for Hematological Malignancies.

K. Rex, J. Canon, B. Herberich, 2019, Journal of medicinal chemistry.

Discovery and Optimization of Quinazolinone-pyrrolopyrrolones as Potent and Orally Bioavailable Pan-Pim Kinase Inhibitors.

K. Rex, B. Herberich, Matthew R. Lee, 2016, Journal of medicinal chemistry.

Discovery and Optimization of Macrocyclic Quinoxaline-pyrrolo-dihydropiperidinones as Potent Pim-1/2 Kinase Inhibitors.

K. Rex, B. Herberich, Matthew R. Lee, 2016, ACS medicinal chemistry letters.

Discovery of 5-(1H-indol-5-yl)-1,3,4-thiadiazol-2-amines as potent PIM inhibitors.

Matthew R. Lee, A. Tasker, Bin Wu, 2015, Bioorganic & medicinal chemistry letters.

Analysis of Polyubiquitin Conjugates Reveals That the Rpn10 Substrate Receptor Contributes to the Turnover of Multiple Proteasome Targets*S

Thibault Mayor, Johannes Graumann, R. Deshaies, 2005, Molecular & Cellular Proteomics.

Quantitative measurement of the requirement of diverse protein degradation pathways in MHC class I peptide presentation

David J. Sherman, Jennifer L Mamrosh, Michael J. Sweredoski, 2023, Science advances.

Human mismatch repair genes and their association with hereditary non-polyposis colon cancer.

R. Kolodner, J. Burn, M. Kane, 1994, Cold Spring Harbor symposia on quantitative biology.

Nucleotide Binding by the HIV‐1 Integrase Protein In Vitro

C. Farnet, J. Lipford, S. Worland, 1994, Journal of acquired immune deficiency syndromes.

The discovery of novel 3-(pyrazin-2-yl)-1H-indazoles as potent pan-Pim kinase inhibitors.

Matthew R. Lee, Xin Huang, A. Tasker, 2015, Bioorganic & medicinal chemistry letters.

Structure of the Human MLH 1 Locus and Analysis of a Large Hereditary Nonpolyposis Colorectal Carcinoma Kindred for mihi Mutations '

D. Bishop, R. Kolodner, J. Burn, 2006 .

mlh 1 Mutations Hereditary Nonpolyposis Colorectal Carcinoma Kindred for Locus and Analysis of a Large MLH 1 Structure of the Human Updated

D. Bishop, R. Kolodner, J. Burn, 2006 .

mlh1 Mutations Hereditary Nonpolyposis Colorectal Carcinoma Kindred for Locus and Analysis of a Large MLH1 Structure of the Human

Elizabeth, J. Burn, P. Morrison, 2006 .

Abstract 4484: Discovery and in vitro characterization of AMG 510–a potent and selective covalent small-molecule inhibitor of KRASG12C

J. McCarter, K. Rex, J. Canon, 2019, Experimental and Molecular Therapeutics.

LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers

R. Heist, K. Rex, J. Lipford, 2024, bioRxiv.